YOLFTbeta
67

ACRO Biomedical Co., Ltd.

6748 · TWO · Healthcare / Biotechnology

196.00TWD+26.50 (+15.63%)

Price History

Full chart

Market Stats

Previous Close169.50
Open169.50
Day Range169.50 – 205.50
52-Week Range57.40 – 310.00
Volume774.45K
Market Cap15.48B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.20
Dividend Yield0.00%
Beta0.22
50-Day Avg189.98
200-Day Avg115.73

About

ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials in Taiwan, Vietnam, and internationally. The company engages in manufacturing medical devices and cosmetics; research, design, production, and sales of biological tissue implants; and dental and orthopedic implants, collagen, and related derivative products. It also offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. ACRO Biomedical Co., Ltd. was founded in 2014 and is based in Kaohsiung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Dar-Jen Hsieh
  • HeadquartersNo.57, Luke 2nd Road, Kaohsiung, Taiwan, 82151, Taiwan
  • Websitehttps://www.acrobiomedical.com

Leadership

  • Dr. Dar-Jen HsiehChairman & CEO
  • Min He WangAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-18.03M21.83M27.63M51.06M44.23M38.26M
Growth (%)--+21.04%+26.59%+84.79%-13.38%-13.51%
Cost of Revenue-9.46M7.29M14.21M11.95M18.04M19.73M
Gross Profit-8.57M14.54M13.43M39.12M26.19M18.53M
Gross Margin-47.55%66.62%48.59%76.60%59.21%48.43%
Operating Expense-64.54M68.10M76.20M87.78M92.69M111.41M
Operating Income--55.97M-53.55M-62.77M-48.67M-66.50M-92.89M
Operating Margin--310.35%-245.35%-227.17%-95.31%-150.35%-242.80%
EBITDA-45.17M-37.38M-41.18M-51.57M-30.18M-48.31M-65.90M
EBITDA Margin--207.28%-188.67%-186.63%-59.10%-109.21%-172.26%
Net Income--50.02M-50.77M-60.88M-41.42M-62.09M-82.66M
Net Income Margin--277.37%-232.61%-220.33%-81.11%-140.37%-216.06%
R&D-31.70M26.04M27.85M28.64M25.72M30.83M
R&D as % of Total Revenue-175.81%119.31%100.77%56.09%58.14%80.59%
Interest Expense122.00K103.00K88.00K100.00K262.00K286.00K224.00K
Interest Expense % of Total Revenue-0.57%0.40%0.36%0.51%0.65%0.59%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets148.46M203.43M151.28M398.53M716.74M655.33M1.13B
Total Liabilities23.01M25.02M21.27M19.92M30.66M29.05M28.11M
Total Equity125.45M178.41M130.02M378.61M686.08M626.28M1.10B
Cash55.46M45.66M32.26M281.85M544.16M191.75M770.67M
Total Debt16.04M16.76M13.37M11.82M21.66M15.85M-
Net Debt-39.42M-28.90M-18.90M-270.02M-522.50M-175.90M-

Cash Flow

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-31.33M-47.83M-45.15M-48.27M-43.38M-49.01M
Investing Cash Flow-74.69M36.85M-10.54M-33.59M-304.67M-
Financing Cash Flow96.88M-3.42M304.40M345.28M-5.25M-
Capital Expenditure3.83M3.30M4.44M22.46M30.63M13.95M
Free Cash Flow-35.16M-51.13M-49.59M-70.73M-74.01M-62.96M
FCF to OCF112.24%106.91%109.83%146.54%170.62%128.47%

Key Statistics & Ratios

Market Cap15.48B
Enterprise Value16.39B
Trailing P/E0.00
Forward P/E0.00
Price / Sales293.48
Price / Book16.21
EPS-1.20
Book Value14.96
Revenue (TTM)52.76M
Gross Profit (TTM)33.85M
EBITDA-84.09M
Profit Margin-149.34%
Operating Margin-169.23%
Return on Equity-9.57%
Return on Assets-6.84%
Shares Outstanding71.68M
Shares Float56.52M
Beta0.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%